Advertisement
UK markets close in 6 hours 27 minutes
  • FTSE 100

    8,082.77
    +37.96 (+0.47%)
     
  • FTSE 250

    19,797.09
    -2.63 (-0.01%)
     
  • AIM

    755.50
    +0.63 (+0.08%)
     
  • GBP/EUR

    1.1630
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2429
    -0.0023 (-0.19%)
     
  • Bitcoin GBP

    53,510.83
    +164.02 (+0.31%)
     
  • CMC Crypto 200

    1,435.91
    +11.81 (+0.83%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.11
    -0.25 (-0.30%)
     
  • GOLD FUTURES

    2,332.20
    -9.90 (-0.42%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,206.65
    +69.00 (+0.38%)
     
  • CAC 40

    8,117.86
    +12.08 (+0.15%)
     

NVO’s Tresiba and Xultophy Could See Solid Growth in 2018

NVO’s Tresiba and Xultophy Could See Solid Growth in 2018

Novo Nordisk’s (NVO) Tresiba reported revenues of 1.76 billion Danish kroner in the first quarter compared to 1.49 billion Danish kroner in the first quarter of 2017, which reflected ~18.0% YoY (year-over-year) growth.